Results 41 to 50 of about 1,128 (134)
Public Health Challenges, Volume 5, Issue 3, September 2026.ABSTRACT Under‐5 child mortality due to vaccine preventable diseases (VPDs) contributes to an estimated burden of ∼5.2 million deaths globally, mostly within low‐ and middle‐income countries (LMICs). Despite ongoing efforts to expand immunisation coverage, gaps in immunisation remain a persistent public health concern, underscoring the need to examine ...
Mansi Malik +3 more
wiley +1 more source
Public Health Challenges, Volume 5, Issue 3, September 2026.Analysis of 10,428 outpatient consultations among school‐aged children attending Ho Polyclinic, Ghana (2018–2022), showed that three conditions accounted for 77.4% of all morbidity: skin conditions (38.3%), malaria (23.0%), and respiratory conditions (16.1%).
Anthoinette Adesope Ekuban, Frank Baiden
wiley +1 more source
Human Vaccines & Immunotherapeutics, 2017 Quantification of pneumococcal conjugate vaccines (PCVs) herd effects are mainly performed on invasive pneumococcal disease (IPD) but there is conflicting evidence regarding herd effects of PCVs on non-IPD pneumococcal community-acquired pneumonia.
Cornelis H. van Werkhoven
doaj +1 more source
Increased Invasive Pneumococcal Disease, North East England, UK
Emerging Infectious Diseases, 2017 Since April 2014, invasive pneumococcal disease incidence has increased substantially across North East England, United Kingdom, reversing the decline that followed the 2006 introduction of pneumococcal conjugate vaccines.
Catherine Houseman +4 more
doaj +1 more source
Reactivation of a Bacillus Calmette–Guérin Scar Following Routine Infant Vaccination
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT A 4‐month‐old infant developed erythema and induration at a Bacillus Calmette–Guérin (BCG) scar shortly after routine DTaP‐IPV‐Hib and pneumococcal vaccination. Laboratory findings were normal, and the lesion resolved spontaneously without treatment.
Fatih Demircioğlu +1 more
wiley +1 more source
Next-Generation Whole-Cell Pneumococcal Vaccine
Vaccines, 2019 Streptococcus pneumoniae remains a major public health hazard. Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited ...
Victor Morais +2 more
doaj +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Bloodstream infections (BSIs) pose a significant global health challenge, particularly in developing countries. Neonates are highly vulnerable due to underdeveloped immune systems and immature physical barriers, a risk amplified by poor hygiene and limited healthcare access in low‐ and middle‐income countries (LMICs), leading to an ...
Alex Odoom +4 more
wiley +1 more source
The New Era of Pneumococcal Vaccination in Adults: What Is Next?
VaccinesStreptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis in children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia and meningitis, pose a ...
Lale Ozisik
doaj +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Non‐typeable Streptococcus pneumoniae (NT‐Sp) strains lack detectable capsules and are often missed by traditional serotyping. While associated primarily with asymptomatic carriage, NT‐Sp has emerged as a key player in antimicrobial resistance (AMR) gene dissemination and serotype replacement in the post‐vaccine era. This systematic
Robert K. Reeks +2 more
wiley +1 more source